Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants

View ORCID ProfileHans C. Leier, View ORCID ProfileTimothy A. Bates, Zoe L. Lyski, Savannah K. McBride, David X. Lee, View ORCID ProfileFelicity J. Coulter, View ORCID ProfileJames R. Goodman, View ORCID ProfileZhengchun Lu, Marcel E. Curlin, View ORCID ProfileWilliam B. Messer, View ORCID ProfileFikadu G. Tafesse
doi: https://doi.org/10.1101/2021.04.25.21256049
Hans C. Leier
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hans C. Leier
Timothy A. Bates
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timothy A. Bates
Zoe L. Lyski
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savannah K. McBride
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David X. Lee
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felicity J. Coulter
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Felicity J. Coulter
James R. Goodman
2Medical Scientist Training Program, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James R. Goodman
Zhengchun Lu
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhengchun Lu
Marcel E. Curlin
3Division of Infectious Diseases, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tafesse@ohsu.edu messer@ohsu.edu curlin@ohsu.edu
William B. Messer
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
3Division of Infectious Diseases, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William B. Messer
  • For correspondence: tafesse@ohsu.edu messer@ohsu.edu curlin@ohsu.edu
Fikadu G. Tafesse
1Department of Molecular Microbiology & Immunology, Oregon Health & Science University; Portland, OR 97239, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fikadu G. Tafesse
  • For correspondence: tafesse@ohsu.edu messer@ohsu.edu curlin@ohsu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We compared the serum neutralizing antibody titers before and after two doses of the BNT162b2 COVID-19 vaccine in ten individuals who recovered from SARS-CoV-2 infection prior to vaccination to 20 individuals with no history of infection, against clinical isolates of B.1.1.7, B.1.351, P.1, and the original SARS-CoV-2 virus. Vaccination boosted pre-existing levels of anti-SARS-CoV-2 spike antibodies 10-fold in previously infected individuals, but not to levels significantly higher than those of uninfected vaccinees. However, neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees against every variant tested: 5.2-fold against B.1.1.7, 6.5-fold against B.1.351, 4.3-fold against P.1, and 3.4-fold against original SARS-CoV-2. Our study indicates that a first-generation COVID-19 vaccine provides broad protection from SARS-CoV-2variants in individuals with previous infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding was provided by the M.J. Murdock Charitable Trust, National Institutes of Health training grant T32AI747225, Oregon Health & Science University Innovative IDEA grant 1018784, and National Institutes of Health grant R01AI145835.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was conducted in accordance with the Oregon Health & Science University Institutional Review Board (IRB#00022511).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data in this manuscript is available upon request from the corresponding authors, M.E.C. (curlin@ohsu.edu), W.B.M. (messer@ohsu.edu), and F.G.T. (tafesse@ohsu.edu).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted April 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
Hans C. Leier, Timothy A. Bates, Zoe L. Lyski, Savannah K. McBride, David X. Lee, Felicity J. Coulter, James R. Goodman, Zhengchun Lu, Marcel E. Curlin, William B. Messer, Fikadu G. Tafesse
medRxiv 2021.04.25.21256049; doi: https://doi.org/10.1101/2021.04.25.21256049
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
Hans C. Leier, Timothy A. Bates, Zoe L. Lyski, Savannah K. McBride, David X. Lee, Felicity J. Coulter, James R. Goodman, Zhengchun Lu, Marcel E. Curlin, William B. Messer, Fikadu G. Tafesse
medRxiv 2021.04.25.21256049; doi: https://doi.org/10.1101/2021.04.25.21256049

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8987)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1958)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10808)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1903)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)